Chénard-Poirier, Maxime http://orcid.org/0000-0001-5800-0124
Hansen, Aaron R.
Gutierrez, Martin E.
Rasco, Drew
Xing, Yan
Chen, Lin-Chi
Zhou, Heng
Webber, Andrea L.
Freshwater, Tomoko
Sharma, Manish R.
Article History
Received: 20 December 2023
Accepted: 1 February 2024
First Online: 14 March 2024
Declarations
:
: All procedures performed in this study were in accordance with local and/or national regulations and with the Declaration of Helsinki. The study protocol was approved by the institutional review board or independent ethics committee at each site.
: Written informed consent was obtained from all individual patients included in the study.
: Maxime Chénard-Poirier: Advisory board: Incyte, Merck & Co., Inc., Rahway, NJ, USA, Pfizer, and Bristol Myers Squibb. Aaron R. Hansen: Honoraria from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD), AstraZeneca, MedImmune, Pfizer, GSK, Novartis, and Bristol Myers Squibb; Consulting or advisory role for Genentech, MSD, GSK, Bristol Myers Squibb, Novartis, Boston Biomedical, and Boehringer Ingelheim; Research funding to institution from Karyopharm Therapeutics, MSD, Bristol Myers Squibb, Boehringer Ingelheim, GSK, Novartis, Genentech, and Janssen. Martin E. Gutierrez: Advisory Board: Sanofi, Incyte, Boehringer Ingelheim. Consultant: Guardant. Stock/Shares: COTA/OMI. Drew Rasco: Research funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA to support study conduct. Yan Xing: None disclosed. Lin-Chi Chen, Heng Zhou, Andrea L. Webber, Tomoko Freshwater: Employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and stockholders in Merck & Co., Inc., Rahway, NJ, USA. Manish R. Sharma: Stockholder in Merck & Co., Inc., Rahway, NJ, USA.